About Gennex Laboratories Limited
Data last updated: 22 December 2025
Gennex Laboratories Limited is a public limited company based in Medak, Telangana, India. It specialises in api manufacturers, a part of the broader pharmaceuticals sector. Incorporated on 29 March 1990, the company has been in operation for over 36 years.
Registered with ROC Hyderabad under CIN L24230TG1990PLC011168. Listed.
Capital: an authorised share capital of ₹25 Cr and a paid-up capital of ₹24.29 Cr. Formerly known as Prudential Pharmaceuticals Limited and Pharmasia Drugs and Chemicals Private Limited. It is led by directors including Shilpa Bung and Ranga Rao Pantulu Avasarala.
Last AGM: 30 September 2024. Financial statements filed for year ended 31 March 2024. Office: 133 Bollaram Jinnaram, Medak, Telangana, India – 502325.
As per the financials filed for FY 2024, the company reported a revenue of ₹91.62 Cr, a growth of 32% compared to the previous year.
The company has a workforce of approximately 103 employees as per the latest available data. Its group structure includes 1 subsidiary.
The company is associated with 1 brand - Gennex Laboratories. As per MCA filings, the company has open charges of ₹65.75 Cr and satisfied charges of ₹26.13 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website gennexlab.com.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media
-
Registered Address133 Bollaram Jinnaram, Medak, Telangana, India – 502325
-
IndustryPharma, API Manufacturers
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Name History of Gennex Laboratories Limited
Gennex Laboratories Limited has undergone 3 name changes throughout its history. The company was previously known as Prudential Pharmaceuticals Limited, Pharmasia Drugs And Chemicals Private Limited, and Pharmasia Drugs And Chemicals Limited. The current legal name is Gennex Laboratories Limited, reflecting the company's evolution and rebranding over time.
| Company Name | Status |
|---|---|
| Gennex Laboratories Limited | Current |
| Prudential Pharmaceuticals Limited | Previous |
| Pharmasia Drugs And Chemicals Private Limited | Previous |
| Pharmasia Drugs And Chemicals Limited | Previous |
CIN History of Gennex Laboratories Limited
Gennex Laboratories Limited has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L24230TG1990PLC011168, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24230TG1990PLC011168 | Current |
| L24230AP1990PLC011168 | Previous |
| L24230AP1990PTC011168 | Previous |
Associated Brands with Gennex Laboratories Limited
Gennex Laboratories Limited operates one associated brand: Gennex Laboratories. These brands represent Gennex Laboratories Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| APIs are manufactured, marketed, and exported by Gennex Laboratories. | gennexlab.com |
Competitors & Alternatives of Gennex Laboratories Limited
Brands and companies operating in the same space as Gennex Laboratories Limited include Concord Biotech, BDR Pharmaceuticals Internationals, Almac Group and 7 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Concord Biotech
|
APIs and enzymes are manufactured through fermentation by the CDMO. | Ahmedabad, India, India | 2000 |
BDR Pharmaceuticals Internationals
|
APIs and finished products are developed and manufactured. | Mumbai, India, India | 2003 |
Almac Group
|
Integrated CDMO services for biopharma R&D and manufacturing are offered. | Craigavon, United Kingdom, United Kingdom | 2001 |
Indoco Remedies
|
APIs manufacturing and formulation services are provided in therapeutic segments. | Mumbai, India, India | 1947 |
Pharmaceutics International
|
Pharmaceutical dosage forms are manufactured by this CDMO. | Hunt Valley, United States, United States | 1994 |
Aurobindo Pharma
|
Generic biocatalytic solutions are provided for pharmaceutical applications. | Hyderabad, India, India | 1986 |
Seqens
|
Contract manufacturing services for small molecules and peptides are provided. | Ecully, France, France | 2003 |
Asymchem
|
APIs and peptides are developed and manufactured by Asymchem. | Morrisville, United States, United States | 1995 |
Aptuit
|
Contract research and development services for small molecules are offered. | Greenwich, United States, United States | 2004 |
Continuus Pharma
|
MIT-Novartis spinoff offering continuous manufacturing solutions to remove the proverbial wall between API and FDF manufacturing in small molecule development | Woburn, United States, United States | 2012 |
Business Activity of Gennex Laboratories Limited
Gennex Laboratories Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
Auditor Details of Gennex Laboratories Limited
Gennex Laboratories Limited is audited by R PUGALIA & COMPANY (ICAI peer reviewed, certificate valid till 2026-08-31) for the financial year 2026, as reported in its BSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| R PUGALIA & COMPANY (ICAI peer reviewed, certificate valid till 2026-08-31) | FY 2026 | Statement on impact of audit qualification |
Board of Directors of Gennex Laboratories Limited
Gennex Laboratories Limited is currently managed by 9 directors, with 16 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Shilpa Bung | Director | 01 Oct 2024 | 1 Years 9 Months | Current |
|
Ranga Rao Pantulu Avasarala
Also directs:
Gennex Laboratories Limited
|
Director | 21 Dec 2020 | 5 Years 6 Months | Current |
|
Amudala Sreeramulu Nageswar Rao
Also directs:
Gennex Laboratories Limited, Kmc Constructions Limited, Basel Practitioners Private Limited and 1 more
|
Director | 21 Dec 2020 | 5 Years 6 Months | Current |
|
Dinesh Kumar Kejriwal
Also directs:
Gennex Laboratories Limited, Deccan Remedies Ltd
|
Company Secretary | 20 Apr 2023 | 3 Years 2 Months | Current |
|
Arihant Baid
Also directs:
Gennex Laboratories Limited, Boujee Foods Llp, Prudential Holdings Pvt. Ltd. and 5 more
|
Managing Director | 18 May 2012 | 14 Years 1 Months | Current |
|
China Dharma Rao Sangeetrao
Also directs:
Gennex Laboratories Limited
|
Additional Director | 12 Mar 2024 | 2 Years 3 Months | Current |
Financials of Gennex Laboratories Limited FY 2026 filings available
Gennex Laboratories Limited reported revenue of ₹172.74 Cr (up 25.26% YoY) for FY 2026. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹172.74 Cr | ₹137.9 Cr | ₹86.71 Cr | ₹65.6 Cr | ₹61.21 Cr | ₹59.65 Cr | ₹55.62 Cr | ₹55.8 Cr |
| Other Income | ₹8.25 Cr | ₹10.43 Cr | ₹4.91 Cr | ₹3.95 Cr | ₹1.38 Cr | ₹52.44 Lakh | ₹95.14 Lakh | ₹78.25 Lakh |
| Total Income | ₹180.99 Cr | ₹148.33 Cr | ₹91.62 Cr | ₹69.56 Cr | ₹62.6 Cr | ₹60.17 Cr | ₹56.57 Cr | ₹56.59 Cr |
| Cost of Materials Consumed | ₹139.62 Cr | ₹100.59 Cr | ₹57.88 Cr | ₹46.91 Cr | ₹40.01 Cr | ₹34.19 Cr | ₹35.13 Cr | ₹34.68 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹40.52 Lakh |
| Changes in Inventories | -₹11.09 Cr | -₹3.51 Cr | -₹9.03 Cr | -₹7 Cr | -₹1.91 Cr | ₹1.53 Cr | -₹1.51 Cr | -₹2.39 Cr |
| Employee Benefit Expense | ₹8.04 Cr | ₹8.35 Cr | ₹7.79 Cr | ₹7.87 Cr | ₹6.97 Cr | ₹7.21 Cr | ₹6.81 Cr | ₹6.12 Cr |
| Finance Costs | ₹4.2 Cr | ₹3.61 Cr | ₹3.08 Cr | ₹1.35 Cr | ₹87.74 Lakh | ₹74.35 Lakh | ₹75.36 Lakh | ₹79.38 Lakh |
| Depreciation & Amortisation | ₹2.65 Cr | ₹1.99 Cr | ₹2.37 Cr | ₹91.94 Lakh | ₹78.85 Lakh | ₹88.07 Lakh | ₹1.01 Cr | ₹98.47 Lakh |
| Other Expenses | ₹14.34 Cr | ₹15.9 Cr | ₹13.04 Cr | ₹13.12 Cr | ₹10.76 Cr | ₹10.19 Cr | ₹11.94 Cr | ₹12.96 Cr |
| Total Expenses | ₹157.75 Cr | ₹126.93 Cr | ₹75.13 Cr | ₹63.18 Cr | ₹57.5 Cr | ₹54.74 Cr | ₹54.13 Cr | ₹53.56 Cr |
| Profit Before Exceptional Items & Tax | ₹23.24 Cr | ₹21.4 Cr | ₹16.49 Cr | ₹6.37 Cr | ₹5.09 Cr | ₹5.43 Cr | ₹2.44 Cr | ₹3.03 Cr |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | -₹37.13 Lakh | ₹10.86 Lakh | ₹0 |
| Profit Before Tax | ₹23.24 Cr | ₹21.4 Cr | ₹16.49 Cr | ₹6.37 Cr | ₹5.09 Cr | ₹5.06 Cr | ₹2.55 Cr | ₹3.03 Cr |
| Total Tax Expense | ₹2.26 Cr | ₹3.27 Cr | ₹3.32 Cr | ₹1.45 Cr | ₹1.17 Cr | ₹1.02 Cr | ₹69.23 Lakh | ₹80.64 Lakh |
| Net Profit | ₹20.98 Cr | ₹18.12 Cr | ₹13.18 Cr | ₹4.92 Cr | ₹3.92 Cr | ₹4.04 Cr | ₹1.86 Cr | ₹2.14 Cr |
| attributable to Owners | ₹18.51 Cr | - | - | - | - | - | ₹0 | ₹0 |
| attributable to NCI | ₹2.52 Cr | - | - | - | - | - | ₹0 | ₹0 |
| Other Comprehensive Income | ₹5.19 Lakh | ₹0 | -₹1.8 Cr | ₹1.27 Cr | ₹18.23 Lakh | ₹0 | ₹0 | ₹0 |
| Total Comprehensive Income | ₹21.03 Cr | ₹18.12 Cr | ₹11.37 Cr | ₹6.19 Cr | ₹4.11 Cr | ₹4.04 Cr | ₹1.86 Cr | ₹2.14 Cr |
| EBITDA (computed) | ₹30.08 Cr | ₹27 Cr | ₹21.94 Cr | ₹8.65 Cr | ₹6.76 Cr | ₹7.06 Cr | ₹4.2 Cr | ₹4.81 Cr |
| Basic EPS | ₹0.76 | ₹0.79 | ₹0.67 | ₹0.35 | ₹0.33 | ₹0.32 | ₹0.15 | ₹0.17 |
| Diluted EPS | ₹0.76 | ₹0.78 | ₹0.61 | ₹0.35 | ₹0.33 | ₹0.32 | ₹0.15 | ₹0.17 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | ₹348.68 Cr | ₹256.04 Cr | ₹229.99 Cr | ₹132.32 Cr | ₹68.03 Cr | ₹58.9 Cr | ₹56.94 Cr | ₹51.82 Cr |
| Non-current Assets | ₹84.02 Cr | ₹74.91 Cr | ₹68.17 Cr | ₹83.63 Cr | ₹20.84 Cr | ₹21.23 Cr | ₹21.98 Cr | ₹22.78 Cr |
| Current Assets | ₹264.66 Cr | ₹181.13 Cr | ₹161.81 Cr | ₹48.68 Cr | ₹47.18 Cr | ₹37.67 Cr | ₹34.97 Cr | ₹29.04 Cr |
| Property, Plant & Equipment | ₹57.8 Cr | ₹56.61 Cr | ₹52.7 Cr | ₹67.63 Cr | ₹13.7 Cr | ₹14.13 Cr | ₹14.93 Cr | ₹15.64 Cr |
| Inventories | ₹53.89 Cr | ₹35.94 Cr | ₹25.17 Cr | ₹15.69 Cr | ₹7.74 Cr | ₹5.02 Cr | ₹7.44 Cr | ₹5.33 Cr |
| Trade Receivables | ₹43.56 Cr | ₹14.16 Cr | ₹17.81 Cr | ₹9.42 Cr | ₹11.31 Cr | ₹8.95 Cr | ₹6.28 Cr | ₹10.4 Cr |
| Cash & Equivalents | ₹5.79 Lakh | ₹55.28 Lakh | ₹47.86 Lakh | ₹56.29 Lakh | ₹32.12 Lakh | ₹18.61 Lakh | ₹19.37 Lakh | ₹19.51 Lakh |
| Equity (Net Worth) | ₹232.84 Cr | ₹194.59 Cr | ₹176.46 Cr | ₹86.52 Cr | ₹43.82 Cr | ₹39.71 Cr | ₹35.67 Cr | ₹33.91 Cr |
| Equity Share Capital | ₹24.29 Cr | ₹22.74 Cr | ₹22.74 Cr | ₹18.02 Cr | ₹12.65 Cr | ₹12.65 Cr | ₹12.65 Cr | ₹12.65 Cr |
| Borrowings (Non-current) | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Borrowings (Current) | ₹35.95 Cr | ₹10.22 Cr | ₹5.72 Cr | ₹1.05 Cr | ₹10.12 Cr | ₹7.36 Cr | ₹4.98 Cr | ₹4.54 Cr |
| Total Debt (computed) | ₹35.95 Cr | ₹10.22 Cr | ₹5.72 Cr | ₹1.05 Cr | ₹10.12 Cr | ₹7.36 Cr | ₹4.98 Cr | ₹4.54 Cr |
| Current Liabilities | ₹72.4 Cr | ₹44.55 Cr | ₹40.3 Cr | ₹29.51 Cr | ₹24.21 Cr | ₹19.04 Cr | ₹20.86 Cr | ₹17.3 Cr |
| Total Liabilities | ₹115.84 Cr | ₹61.45 Cr | ₹53.52 Cr | ₹45.8 Cr | ₹24.21 Cr | ₹19.19 Cr | ₹21.27 Cr | ₹17.92 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | -₹63.65 Cr | -₹10.8 Cr | -₹46.69 Cr | ₹23.72 Cr | ₹6.64 Cr |
| Investing Cash Flow | -₹4.8 Cr | ₹82.37 Lakh | ₹18.91 Cr | -₹38.37 Cr | -₹1.26 Cr |
| Financing Cash Flow | ₹65.3 Cr | ₹4.57 Cr | ₹73.68 Cr | ₹21.03 Cr | ₹1.87 Cr |
| Capital Expenditure | ₹11.94 Cr | ₹8.95 Cr | ₹0 | ₹39.79 Cr | ₹38.97 Lakh |
| Free Cash Flow (computed) | -₹75.59 Cr | -₹19.74 Cr | -₹46.69 Cr | -₹16.07 Cr | ₹6.25 Cr |
| Dividends Paid | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Net Change in Cash | -₹3.15 Cr | -₹5.41 Cr | ₹45.91 Cr | ₹6.38 Cr | ₹7.24 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹60.96 Cr | ₹40.37 Cr | ₹37.24 Cr | ₹34.18 Cr | ₹40.33 Cr | ₹37.71 Cr | ₹31.55 Cr | ₹28.32 Cr |
| Other Income | ₹1.32 Cr | ₹2.59 Cr | ₹2.06 Cr | ₹2.28 Cr | ₹3.83 Cr | ₹2.3 Cr | ₹1.83 Cr | ₹2.46 Cr |
| Total Income | ₹62.27 Cr | ₹42.96 Cr | ₹39.3 Cr | ₹36.45 Cr | ₹44.16 Cr | ₹40.01 Cr | ₹33.38 Cr | ₹30.79 Cr |
| Cost of Materials Consumed | ₹55.29 Cr | ₹29.96 Cr | ₹30.56 Cr | ₹23.82 Cr | ₹33.06 Cr | ₹28.62 Cr | ₹20.89 Cr | ₹18.02 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | -₹2.67 Cr | -₹1.66 Cr | -₹5.15 Cr | -₹1.62 Cr | -₹76.05 Lakh | -₹94.45 Lakh | -₹1.58 Cr | -₹22.28 Lakh |
| Employee Benefit Expense | ₹1.17 Cr | ₹2.34 Cr | ₹1.84 Cr | ₹2.69 Cr | ₹2.08 Cr | ₹2.06 Cr | ₹1.92 Cr | ₹2.29 Cr |
| Finance Costs | ₹1.08 Cr | ₹1.11 Cr | ₹1.03 Cr | ₹97.9 Lakh | ₹1.2 Cr | ₹84.07 Lakh | ₹1.11 Cr | ₹73.17 Lakh |
| Depreciation & Amortisation | ₹1.16 Cr | ₹51.85 Lakh | ₹46.5 Lakh | ₹50.4 Lakh | ₹54.32 Lakh | ₹49.73 Lakh | ₹21.86 Lakh | ₹45.29 Lakh |
| Other Expenses | ₹1.58 Cr | ₹3.75 Cr | ₹4.5 Cr | ₹4.22 Cr | ₹4.09 Cr | ₹3.11 Cr | ₹4.7 Cr | ₹4 Cr |
| Total Expenses | ₹57.61 Cr | ₹36.01 Cr | ₹33.24 Cr | ₹30.59 Cr | ₹40.21 Cr | ₹34.19 Cr | ₹27.26 Cr | ₹25.28 Cr |
| Profit Before Exceptional Items & Tax | ₹4.67 Cr | ₹6.94 Cr | ₹6.06 Cr | ₹5.87 Cr | ₹3.95 Cr | ₹5.82 Cr | ₹6.12 Cr | ₹5.51 Cr |
| Exceptional Items | ₹0 | -₹30 Lakh | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹4.67 Cr | ₹6.64 Cr | ₹6.06 Cr | ₹5.87 Cr | ₹3.95 Cr | ₹5.82 Cr | ₹6.12 Cr | ₹5.51 Cr |
| Total Tax Expense | ₹20.89 Lakh | ₹65 Lakh | ₹55 Lakh | ₹85 Lakh | ₹88.47 Lakh | ₹75 Lakh | ₹75 Lakh | ₹85 Lakh |
| Net Profit | ₹4.46 Cr | ₹5.99 Cr | ₹5.51 Cr | ₹5.02 Cr | ₹3.07 Cr | ₹5.07 Cr | ₹5.37 Cr | ₹4.66 Cr |
| attributable to Owners | ₹3.79 Cr | ₹5.24 Cr | ₹5.03 Cr | ₹4.59 Cr | - | ₹4.64 Cr | ₹4.83 Cr | ₹0 |
| attributable to NCI | ₹72.03 Lakh | ₹75.51 Lakh | ₹47.92 Lakh | ₹42.48 Lakh | - | ₹42.14 Lakh | ₹54.52 Lakh | ₹0 |
| Other Comprehensive Income | ₹5.19 Lakh | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Total Comprehensive Income | ₹4.51 Cr | ₹5.99 Cr | ₹5.51 Cr | ₹5.02 Cr | ₹3.07 Cr | ₹5.07 Cr | ₹5.37 Cr | ₹4.66 Cr |
| EBITDA (computed) | ₹6.9 Cr | ₹8.57 Cr | ₹7.56 Cr | ₹7.35 Cr | ₹5.7 Cr | ₹7.15 Cr | ₹7.45 Cr | ₹6.69 Cr |
| Basic EPS | ₹0.16 | ₹0.22 | ₹0.21 | ₹0.22 | ₹0.13 | ₹0.22 | ₹0.21 | ₹0.21 |
| Diluted EPS | ₹0.16 | ₹0.22 | ₹0.21 | ₹0.21 | ₹0.13 | ₹0.22 | ₹0.21 | ₹0.21 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹119.86 Cr | ₹94.58 Cr | ₹66.8 Cr | ₹65.1 Cr | ₹61.21 Cr | ₹59.65 Cr | ₹55.8 Cr |
| Other Income | ₹8.14 Cr | ₹9.22 Cr | ₹4.3 Cr | ₹3.4 Cr | ₹1.38 Cr | ₹52.44 Lakh | ₹78.25 Lakh |
| Total Income | ₹128 Cr | ₹103.8 Cr | ₹71.1 Cr | ₹68.5 Cr | ₹62.6 Cr | ₹60.17 Cr | ₹56.59 Cr |
| Cost of Materials Consumed | ₹96.83 Cr | ₹67.18 Cr | ₹40.88 Cr | ₹46.91 Cr | ₹40.01 Cr | ₹34.19 Cr | ₹34.68 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹40.52 Lakh |
| Changes in Inventories | -₹9.29 Cr | -₹70.14 Lakh | -₹2.44 Cr | -₹7 Cr | -₹1.91 Cr | ₹1.53 Cr | -₹2.39 Cr |
| Employee Benefit Expense | ₹6.67 Cr | ₹6.43 Cr | ₹6.05 Cr | ₹7.71 Cr | ₹6.97 Cr | ₹7.21 Cr | ₹6.12 Cr |
| Finance Costs | ₹2.47 Cr | ₹1.58 Cr | ₹1.16 Cr | ₹1.23 Cr | ₹87.74 Lakh | ₹74.35 Lakh | ₹79.38 Lakh |
| Depreciation & Amortisation | ₹96.76 Lakh | ₹76.95 Lakh | ₹81.04 Lakh | ₹74.44 Lakh | ₹78.85 Lakh | ₹88.07 Lakh | ₹98.47 Lakh |
| Other Expenses | ₹12.12 Cr | ₹11.48 Cr | ₹9.89 Cr | ₹12.89 Cr | ₹10.76 Cr | ₹10.19 Cr | ₹12.96 Cr |
| Total Expenses | ₹109.76 Cr | ₹86.74 Cr | ₹56.35 Cr | ₹62.49 Cr | ₹57.5 Cr | ₹54.74 Cr | ₹53.56 Cr |
| Profit Before Exceptional Items & Tax | ₹18.24 Cr | ₹17.06 Cr | ₹14.75 Cr | ₹6.01 Cr | ₹5.09 Cr | ₹5.43 Cr | ₹3.03 Cr |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | -₹37.13 Lakh | ₹0 |
| Profit Before Tax | ₹18.24 Cr | ₹17.06 Cr | ₹14.75 Cr | ₹6.01 Cr | ₹5.09 Cr | ₹5.06 Cr | ₹3.03 Cr |
| Total Tax Expense | ₹2.11 Cr | ₹3.02 Cr | ₹2.96 Cr | ₹1.45 Cr | ₹1.17 Cr | ₹1.02 Cr | ₹80.64 Lakh |
| Net Profit | ₹16.13 Cr | ₹14.04 Cr | ₹11.8 Cr | ₹4.56 Cr | ₹3.92 Cr | ₹4.04 Cr | ₹2.22 Cr |
| Other Comprehensive Income | ₹5.19 Lakh | ₹0 | ₹11.06 Lakh | ₹2.36 Lakh | ₹18.23 Lakh | ₹0 | ₹0 |
| Total Comprehensive Income | ₹16.18 Cr | ₹14.04 Cr | ₹11.91 Cr | ₹4.58 Cr | ₹4.11 Cr | ₹4.04 Cr | ₹2.22 Cr |
| EBITDA (computed) | ₹21.67 Cr | ₹19.42 Cr | ₹16.72 Cr | ₹7.99 Cr | ₹6.76 Cr | ₹7.06 Cr | ₹4.81 Cr |
| Basic EPS | ₹0.67 | ₹0.62 | ₹0.70 | ₹0.26 | ₹0.33 | ₹0.32 | ₹0.18 |
| Diluted EPS | ₹0.67 | ₹0.61 | ₹0.64 | ₹0.26 | ₹0.33 | ₹0.32 | ₹0.18 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Total Assets | ₹273.82 Cr | ₹218.38 Cr | ₹205.34 Cr | ₹96.22 Cr | ₹68.21 Cr | ₹59.08 Cr | ₹51.91 Cr |
| Non-current Assets | ₹35.73 Cr | ₹31.36 Cr | ₹26.35 Cr | ₹24.06 Cr | ₹21.03 Cr | ₹21.42 Cr | ₹22.87 Cr |
| Current Assets | ₹238.09 Cr | ₹187.02 Cr | ₹178.99 Cr | ₹72.16 Cr | ₹47.18 Cr | ₹37.67 Cr | ₹29.04 Cr |
| Property, Plant & Equipment | ₹21.64 Cr | ₹19.65 Cr | ₹15.83 Cr | ₹15.18 Cr | ₹13.7 Cr | ₹14.13 Cr | ₹15.64 Cr |
| Inventories | ₹41.63 Cr | ₹24.59 Cr | ₹16.07 Cr | ₹14.97 Cr | ₹7.74 Cr | ₹5.02 Cr | ₹5.33 Cr |
| Trade Receivables | ₹33.37 Cr | ₹11.89 Cr | ₹13.57 Cr | ₹8.82 Cr | ₹11.31 Cr | ₹8.95 Cr | ₹10.4 Cr |
| Cash & Equivalents | ₹5.26 Lakh | ₹54.95 Lakh | ₹47.71 Lakh | ₹42.02 Lakh | ₹32.12 Lakh | ₹18.61 Lakh | ₹19.51 Lakh |
| Equity (Net Worth) | ₹218.12 Cr | ₹184.8 Cr | ₹170.76 Cr | ₹79.02 Cr | ₹44 Cr | ₹39.89 Cr | ₹34 Cr |
| Equity Share Capital | ₹24.29 Cr | ₹22.74 Cr | ₹22.74 Cr | ₹18.02 Cr | ₹12.65 Cr | ₹12.65 Cr | ₹12.65 Cr |
| Borrowings (Non-current) | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Borrowings (Current) | ₹22.82 Cr | ₹1.24 Cr | ₹84.72 Lakh | ₹98.16 Lakh | ₹10.12 Cr | ₹7.36 Cr | ₹4.54 Cr |
| Total Debt (computed) | ₹22.82 Cr | ₹1.24 Cr | ₹84.72 Lakh | ₹98.16 Lakh | ₹10.12 Cr | ₹7.36 Cr | ₹4.54 Cr |
| Current Liabilities | ₹52.08 Cr | ₹29.11 Cr | ₹32.82 Cr | ₹15.91 Cr | ₹24.21 Cr | ₹19.04 Cr | ₹17.3 Cr |
| Total Liabilities | ₹55.7 Cr | ₹33.59 Cr | ₹34.58 Cr | ₹17.2 Cr | ₹24.21 Cr | ₹19.19 Cr | ₹17.92 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | -₹40.18 Cr | -₹9.56 Cr | -₹33.43 Cr | -₹14.45 Cr | ₹6.64 Cr |
| Investing Cash Flow | ₹1.62 Cr | ₹2.63 Cr | ₹92.72 Lakh | -₹76.51 Lakh | -₹1.26 Cr |
| Financing Cash Flow | ₹35.4 Cr | ₹1.53 Cr | ₹79.01 Cr | ₹21.35 Cr | ₹1.87 Cr |
| Capital Expenditure | ₹5.51 Cr | ₹5.96 Cr | ₹2.84 Cr | ₹2.22 Cr | ₹38.97 Lakh |
| Free Cash Flow (computed) | -₹45.7 Cr | -₹15.52 Cr | -₹36.27 Cr | -₹16.67 Cr | ₹6.25 Cr |
| Dividends Paid | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Net Change in Cash | -₹3.16 Cr | -₹5.4 Cr | ₹46.51 Cr | ₹6.14 Cr | ₹7.24 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹36.71 Cr | ₹28.18 Cr | ₹29.33 Cr | ₹25.64 Cr | ₹23.28 Cr | ₹25.28 Cr | ₹24.69 Cr | ₹21.33 Cr |
| Other Income | ₹1.3 Cr | ₹2.54 Cr | ₹2.04 Cr | ₹2.26 Cr | ₹2.87 Cr | ₹2.07 Cr | ₹1.82 Cr | ₹2.46 Cr |
| Total Income | ₹38.01 Cr | ₹30.71 Cr | ₹31.37 Cr | ₹27.9 Cr | ₹26.15 Cr | ₹27.35 Cr | ₹26.51 Cr | ₹23.79 Cr |
| Cost of Materials Consumed | ₹33.84 Cr | ₹18.15 Cr | ₹26.57 Cr | ₹18.27 Cr | ₹21.45 Cr | ₹20.66 Cr | ₹13.89 Cr | ₹11.19 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | -₹2.53 Cr | ₹1.16 Cr | -₹6.94 Cr | -₹98.8 Lakh | -₹2.81 Cr | -₹2.19 Cr | ₹2.16 Cr | ₹2.13 Cr |
| Employee Benefit Expense | ₹82.82 Lakh | ₹2.09 Cr | ₹1.88 Cr | ₹1.88 Cr | ₹1.89 Cr | ₹1.14 Cr | ₹1.49 Cr | ₹1.9 Cr |
| Finance Costs | ₹63.11 Lakh | ₹68.98 Lakh | ₹55.45 Lakh | ₹59.15 Lakh | ₹53.49 Lakh | ₹40.82 Lakh | ₹46.97 Lakh | ₹29.49 Lakh |
| Depreciation & Amortisation | ₹34.94 Lakh | ₹21.25 Lakh | ₹20.7 Lakh | ₹19.87 Lakh | ₹22.59 Lakh | ₹19.67 Lakh | ₹5.21 Lakh | ₹17.18 Lakh |
| Other Expenses | ₹1.69 Cr | ₹3.15 Cr | ₹3.87 Cr | ₹3.1 Cr | ₹2.68 Cr | ₹2.17 Cr | ₹3.44 Cr | ₹3.19 Cr |
| Total Expenses | ₹34.81 Cr | ₹25.46 Cr | ₹26.13 Cr | ₹23.05 Cr | ₹23.97 Cr | ₹22.39 Cr | ₹21.5 Cr | ₹18.88 Cr |
| Profit Before Exceptional Items & Tax | ₹3.2 Cr | ₹5.25 Cr | ₹5.23 Cr | ₹4.85 Cr | ₹2.18 Cr | ₹4.96 Cr | ₹5.01 Cr | ₹4.92 Cr |
| Exceptional Items | ₹0 | -₹30 Lakh | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹3.2 Cr | ₹4.95 Cr | ₹5.23 Cr | ₹4.85 Cr | ₹2.18 Cr | ₹4.96 Cr | ₹5.01 Cr | ₹4.92 Cr |
| Total Tax Expense | ₹20.89 Lakh | ₹50 Lakh | ₹70 Lakh | ₹70 Lakh | ₹67.47 Lakh | ₹75 Lakh | ₹85 Lakh | ₹75 Lakh |
| Net Profit | ₹2.99 Cr | ₹4.45 Cr | ₹4.53 Cr | ₹4.15 Cr | ₹1.5 Cr | ₹4.21 Cr | ₹4.16 Cr | ₹4.17 Cr |
| Other Comprehensive Income | ₹5.19 Lakh | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Total Comprehensive Income | ₹3.05 Cr | ₹4.45 Cr | ₹4.53 Cr | ₹4.15 Cr | ₹1.5 Cr | ₹4.21 Cr | ₹4.16 Cr | ₹4.17 Cr |
| EBITDA (computed) | ₹4.18 Cr | ₹6.15 Cr | ₹5.99 Cr | ₹5.64 Cr | ₹2.94 Cr | ₹5.56 Cr | ₹5.53 Cr | ₹5.38 Cr |
| Basic EPS | ₹0.13 | ₹0.18 | ₹0.19 | ₹0.18 | ₹0.06 | ₹0.19 | ₹0.18 | ₹0.18 |
| Diluted EPS | ₹0.13 | ₹0.18 | ₹0.19 | ₹0.17 | ₹0.06 | ₹0.19 | ₹0.18 | ₹0.18 |
Shareholding Pattern of Gennex Laboratories Limited
As per the shareholding pattern filed with BSE for the quarter ended Mar 2026, promoters hold 23.63%, domestic institutional investors hold 0.00%, retail and other public shareholders hold 76.37% of Gennex Laboratories Limited. The company had 84,133 shareholders on record.
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Promoters | 23.63% | 23.62% | 23.62% | 19.83% | 18.42% | 18.42% |
| Public | 76.37% | 76.38% | 76.38% | 80.17% | 81.58% | 81.58% |
| Mar 2026 | Mar 2025 | Mar 2024 | |
|---|---|---|---|
| Promoters | 23.63% | 18.42% | 18.42% |
| Public | 76.37% | 81.58% | 81.58% |
| Promoter change (YoY, %pts) | +5.21 | +0.00 | - |
Group Structure of Gennex Laboratories Limited
Gennex Laboratories Limited has 1 subsidiary company. This group structure data is as of FY 2023. The corporate group structure reflects Gennex Laboratories Limited's business expansion strategy and organizational complexity.
| Company Name | CIN | Shares Held |
|---|---|---|
| Deccan Remedies Limited | U72200TG1994PLC016962 | - |
Showing major subsidiaries. Total: 1.
Charges & Borrowings of Gennex Laboratories Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 24 Sep 2025 | Others | ₹1.5 Cr | Open |
| 22 Nov 2024 | Others | ₹6.65 Cr | Open |
| 01 Oct 2024 | Others | ₹5 Cr | Open |
| 31 Oct 2023 | Others | ₹22.5 Lakh | Open |
| 02 Mar 2023 | Axis Bank Limited | ₹4 Lakh | Open |
Total charge records: 11 View all charges
Employees and EPFO Compliance at Gennex Laboratories Limited
Gennex Laboratories Limited has a workforce of 103 employees as of Mar 30, 2024.
Employee Count & EPFO Data of Gennex Laboratories Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Gennex Laboratories Limited
GSTIN & GST Filing Data of Gennex Laboratories Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Gennex Laboratories Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Gennex Laboratories Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Gennex Laboratories Limited
MSME Payment Delays by Gennex Laboratories Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Gennex Laboratories Limited
Subsidiaries & Group Companies of Gennex Laboratories Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Gennex Laboratories Limited with ownership details.
MCA Filings & Documents of Gennex Laboratories Limited
MCA Filings & Documents of Gennex Laboratories Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Gennex Laboratories Limited
Frequently Asked Questions about Gennex Laboratories Limited
Gennex Laboratories Limited is an active public limited company in the pharma sector based in Medak, Telangana, India. It was incorporated on 29 March 1990 (36+ years old) and is registered under CIN L24230TG1990PLC011168. The company has 103 employees.
Gennex Laboratories Limited reported revenue of ₹91.62 Cr for FY 2024 (up 32.00% YoY).
The current directors of Gennex Laboratories Limited are:
The primary industry of Gennex Laboratories Limited is pharma. The company specifically operates in api manufacturers. The company is currently active in this sector.
Yes, Gennex Laboratories Limited is a listed company.
Gennex Laboratories Limited can be reached at the registered office: 133 Bollaram Jinnaram, Medak, Telangana, India – 502325, or through the website gennexlab.com.